A Phase 1b, Proof of Concept, Dose-Ranging Study to Evaluate the Safety of the Coadministration of Ascending Doses of ANS-6637 and Ethanol in Healthy Male Moderate Drinkers
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2018
At a glance
- Drugs ANS 6637 (Primary)
- Indications Alcoholism
- Focus Adverse reactions; Proof of concept
- Sponsors Amygdala Neurosciences
- 12 Sep 2018 Results presented in an Amygdala Neurosciences media release.
- 12 Jan 2018 Status changed from recruiting to completed.
- 18 Oct 2017 According to an Altasciences media release, Altasciences are working with Amygdala Neurosciences to conduct this trial.